The effect of prolonged cisplatin‐based chemotherapy on progression‐free survival in patients with optimal epithelial ovarian cancer: ‘Maintenance’ therapy reconsidered

Gershenson, D. M.; Mitchell, Michele Follen; Atkinson, Neely; Silva, E.G.; Kavanagh, John J.; Morris, Mitchell; Burke, T.; Warner, Douglas; Jt, Wharton

doi:10.1016/0020-7292(93)90500-v

Cited by 9 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that the outcome for patients with stage III or IV ovarian cancer was superior for the cyclic-CAP group compared with the control group (cyclic-CAP, 44%; and control, 9%; estimated 5-year survival rates). 18 The mechanism of the treatment would be cytotoxicity, in which a perfect or near-perfect balance should be achieved between tumor cell growth and tumor cell killing. They concluded that intermittent cisplatin chemotherapy, in which cisplatin, 20 mg/m 2 for 5 days, was administered every 3-4 months for 5 years, seemed to be an effective consolidation therapy for stage-III ovarian cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy

Amikura

Aoki²,

Kase³

et al. 2002

Int J Clin Oncol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy

Amikura

Aoki²,

Kase³

et al. 2002

Int J Clin Oncol

View full text Add to dashboard Cite

“…Thus, it is natural that investigators have desired to explore the potential for a 'consolidation' or 'maintenance' strategy in ovarian cancer to favorably impact survival in individuals who have achieved an excellent response to chemotherapy, have no clinical evidence of disease, but who have a high likelihood of experiencing ultimate progression of their malignancy (8,9) .…”

mentioning

confidence: 99%

“…However, for those patients who have demonstrated inherent sensitivity to platinum-based therapy, it is conceivable that more prolonged treatment might achieve some clinically relevant benefit (8,9) . Thus, the appropriate time, to have randomized patients to additional versus no additional treatment cycles, would have been after inherent sensitivity had been documented (ie, following the initial five to six courses) and not at the time of initiation of chemotherapy.…”

mentioning

confidence: 99%

Consolidation therapy revisited: intravenous chemotherapy

Markman

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

The administration of ‘consolidation’ therapy is designed to maximize the benefits achieved from primary chemotherapy, to both improve progression-free and overall survival. Paclitaxel is an excellent agent to consider for a consolidation strategy in ovarian cancer, based on its activity in the disease, its cycle-specificity, and the lack of serious cumulative toxicity (except for neuropathy). A recently reported randomized trial conducted by the South-west Oncology Group and the Gynecologic Oncology Group revealed that 12-monthly cycles of single-agent paclitaxel (175 mg/m2 over 3 h) improves progression-free survival (PFS), compared to 3-monthly cycles of the agent (median PFS: 28 months versus 21 months, P = 0.0023, and hazard ratio 2.31). Further exploration of consolidation/maintenance therapy in the management of ovarian cancer is indicated, focusing on agents that are easy to administer (eg, oral) and that result in limited cumulative toxicity.

show abstract

“…111 and the EuropeanCanadian intergroup trial, results were similar: The new combination of cisplatin and paclitaxel showed significant superior Table 4. Overview over prospectively randomized [40,[42][43][44] and retrospective [45,46] ). e Retrospective comparison of patients treated in a university (6 courses) or in academic hospitals (9 courses).…”

Section: Introduction Of Paclitaxel Into Treatment Of Advanced Ovariamentioning

confidence: 99%

First-Line Chemotherapy in Advanced Ovarian Cancer: State of the Art and Future Aspects

Bois¹,

Lück²,

Bauknecht³

1999

Oncol Res Treat

View full text Add to dashboard Cite

Over the last 25 years, the principles of treatment for advanced ovarian cancer have not changed. They still consist of primary debulking surgery followed by chemotherapy. Progress in operative and perioperative medicine as well as development of more effective chemotherapies have substantially improved the outcome in these patients. Cornerstones in the development of effective chemotherapies were the introduction of cisplatin in the late 70s and the introduction of paclitaxel in the 90s. Actual standard treatment consisting of a platinum-paclitaxel combination chemotherapy achieves an objective response rate in about 3/4 of patients. Ongoing studies evaluate 3 options to improve efficacy of first-line treatment: (a) incorporation of further non-cross-resistant drugs into first-line regimens; (b) modification of the sequence of treatment modalities; (c) modifications of dose intensity with either intraperitoneal therapy or high-dose chemotherapy with peripheral stem cell support. Future studies will have to focus on how to maintain the high remission rates achieved with primary therapy and translate them into long-term survival.

show abstract

The effect of prolonged cisplatin‐based chemotherapy on progression‐free survival in patients with optimal epithelial ovarian cancer: ‘Maintenance’ therapy reconsidered

Cited by 9 publications

References 0 publications

Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy

Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy

Consolidation therapy revisited: intravenous chemotherapy

First-Line Chemotherapy in Advanced Ovarian Cancer: State of the Art and Future Aspects

Contact Info

Product

Resources

About